- Report
- May 2024
- 264 Pages
Global
From €5237EUR$5,450USD£4,503GBP
- Report
- March 2024
- 110 Pages
Global
From €5717EUR$5,950USD£4,916GBP
- Drug Pipelines
- April 2024
- 260 Pages
Global
From €2883EUR$3,000USD£2,479GBP
- Report
- October 2023
- 140 Pages
Global
From €4276EUR$4,450USD£3,677GBP
- Report
- September 2022
- 30 Pages
Global
From €2642EUR$2,750USD£2,272GBP
- Report
- May 2024
- 200 Pages
From €3988EUR$4,150USD£3,429GBP
- Report
- September 2022
- 342 Pages
Global
From €9128EUR$9,500USD£7,849GBP
Xenical (orlistat) is an anti-obesity drug developed by Roche Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in 1999. It is a lipase inhibitor, meaning it works by blocking the absorption of dietary fat in the intestine. Xenical is the only prescription-strength weight loss medication available in the United States. It is typically prescribed to individuals with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher and other risk factors such as high blood pressure or diabetes.
Xenical is available in capsule form and is taken with meals. It is typically taken three times a day, with each dose taken with a main meal that contains fat. Common side effects include abdominal pain, diarrhea, and flatulence.
The anti-obesity drug market is a rapidly growing industry, with Xenical being one of the most popular medications. It is often prescribed as part of a comprehensive weight loss program that includes diet and exercise.
Some companies in the Xenical market include Roche Pharmaceuticals, GlaxoSmithKline, Novo Nordisk, and Merck & Co. Show Less Read more